Autumn 2025 COVID-19 vaccination campaign: mRNA vaccines for adults and young people: knowledge session

This session provides information about the mRNA COVID-19 vaccine for administration during the autumn 2025 vaccination campaign to those aged 12 years and above who are eligible to receive it. The vaccine is:
- Pfizer BioNTech Comirnaty KP.2 vaccine, 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine. This will generally be referred to as Comirnaty KP.2 30 micrograms/dose throughout this session and is suitable for eligible adults and young people aged 12 years and above

Within this session, except where it is necessary to specify the vaccine product, these will be referred to as (the) mRNA vaccines.

This session is designed to provide healthcare workers with the knowledge they need to administer these vaccines safely and effectively to eligible individuals. It will cover key information including how the vaccines work, how they should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions.

This session covers legal aspects of vaccination. This session must be completed in addition to the vaccine-specific session by any staff member new to COVID-19 vaccination. It may also be freely consulted by experienced vaccinators wishing to revise their knowledge.

After completing this session - you should complete the accompanying knowledge assessment(s) for the vaccine(s) that you will be administering.

The different types of vaccine have different storage, preparation and administration requirements. Vaccines produced by the same manufacturer, may, too, have different requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering and any changes since the last campaign.